Background and purpose: The evidence suggest that patients with dementia after stroke exhibit a cholinergic deficit, therefore they may benefit from treatment with cholinesterase inhibitors such as donepezil. The purpose of this study is to evaluate the efficacy of donepezil for relieving symptoms of Alzheimer's dementia.
Methods: NINDS-AIREN criteria were used to establish inclusion and exclusion criteria: evidence of dementia (impaired memory and two other cognitive domians), evidence of cerebrovascular disease-stroke. From neuroimaging and physical examination and apossible or probable relationship between dementia and cerebrovascular disease were required forenrollment. Patients with diagnosis of Alzheimer's disease or dementia caused by other conditions were excluded. According to these criteria the patients are classiffied as probable or possible Alzheimer dementia.. Patients No 80 men age from 68 tom 78 years 59% men, with probably 70% or possible 30% Alzheimer dementia were randomized to 20 weeks of treatment with donepezil 5 mg one month and 10mg after, 30 patients placebo.
Results: Tabl. Donepezil- treated groupe 5mg and 10mg after showed significant improvment in cognition on Alzheimer Disease Assesment Scale vs placebo, significant improvements in patients global function on the Clinicians interview vs placebo and significant benefits in activites of daily living over placebo on the Alzheimers Disease Functional Assessment and Change Scale.
Conclusion: These study data demonstrate an effective and well-tolerated Tabl. Donepezil treatment for Alzheimer dementia suggesting an important place in the management of this contition.
Biography: Dr.Specialist Psychiatrist and Family Psychotherapist Bundaleska Olivera. Graduated at Medical Faculty “Kiril I Metodij, Skopje”, ‘Year 1982. Specialized as Psychiatist Year 1999. Member of Alzheimer ?ssociation“ Alzheimer Plus”. She is working in Gerontology Institute “13 Noemvri, Skopje”, for 30 years. She is working at stationary part only with dementia. In ambulants she works also with other patology. She has visited more than 15 World Alzheimer Congresses.